JPH08506083A - ボツリヌスb複合体を含有する医薬組成物 - Google Patents
ボツリヌスb複合体を含有する医薬組成物Info
- Publication number
- JPH08506083A JPH08506083A JP6502542A JP50254294A JPH08506083A JP H08506083 A JPH08506083 A JP H08506083A JP 6502542 A JP6502542 A JP 6502542A JP 50254294 A JP50254294 A JP 50254294A JP H08506083 A JPH08506083 A JP H08506083A
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- reconstituted
- toxin
- formulation
- botulinum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.1ml当り104マウスLD50単位またはそれ以下の濃度における複合体の安定 性を維持するための医薬的に許容し得る賦形剤と混合された、ゲル濾過クロマト グラフィーにより測定して少なくとも300KDの分子量を有する複合体を形成する ボツリヌス由来安定化蛋白質と結合したC.botulinumB型神経毒を含有する凍結 乾燥した製剤からなり、そして水溶液中で再構成したときに、その毒性活性の少 なくとも75%を保持する製剤からなる局所的な、部分的な、漸増可能な筋脱神経 を誘発するのに使用される医薬製剤。 2.再構成したときに5.0と7.3との間のpHを有することを特徴とする請求の範 囲第1項記載の医薬製剤。 3.約7.0より低いpHを有する請求の範囲第2項記載の医薬製剤。 4.再構成したときに、その毒性活性の少なくとも90%を保持する請求の範囲 第1項記載の医薬製剤。 5.蛋白質賦形剤がアルブミンおよびゼラチンからなる群から選択されたもの である請求の範囲第1項記載の医薬製剤。 6.安定化蛋白質の少なくとも1種が、C.botulinumにより神経毒と一緒に同 時発現された赤血球細胞凝集因子からなる請求の範囲第1項記載の医薬製剤。 7.実質的に上記の神経毒および安定化蛋白質以外の細菌蛋白質を含有してい ない請求の範囲第1項記載の医薬製剤。 8.随意収縮を可能にしながら不随意収縮を減少させるのに十分な再構成した 組成物の投与量を筋体積内の一点に注射し、そして該投与量を筋体積を通して拡 散させてその部分的脱神経を誘発させることを可能にすることによる、哺乳動物 の筋の体 積を選択的、部分的、一時的、化学的に脱神経する医薬の製造のための請求の範 囲第1項記載に記載された再構成した製剤の使用。 9.筋の予定された体積内の離れた部位に再構成した組成物の個々の投与量を 注射することからなり、そしてこれらの部位の場所的関係が、該体積の全体を少 なくとも部分的に脱神経するのに十分なものである請求の範囲第8項記載の使用 。 10.筋の体積が単一の筋からなり、方法が、上記組成物の単位投与量を筋の神 経支配帯域に注射し、そして該投与量を該神経支配帯域を通して拡散させて筋の 全体の部分的脱神経を誘発させることから請求の範囲第8項記載の使用。 11.筋の神経支配帯域の少なくとも一部分に、随意筋剌激を可能にしながら、 痙れんおよび不随意収縮を減少させるのに十分な量の再構成された製剤を投与す ることによる、病原性神経剌激により誘発された患者の筋の痙れんおよび不随意 収縮を減少する医薬の製造のための請求の範囲第1項記載の再構成された製剤の 使用。 12.筋の神経支配帯域の少なくとも一部分に、随意筋剌激を可能にしながら、 振せん、硬直または痙性を減少させるのに十分な量の再構成された製剤を注射す ることによる、振せん、硬直または痙性を減少する医薬の製造に対する請求の範 囲第1項記載の再構成された製剤の使用。 13.水性媒質中で再構成したときに、その活性の75%以上を保持する凍結乾燥 されたボツリヌス毒素製剤。 14.水性媒質中で再構成したときに、その活性の90%以上を保持する請求の範 囲第13項記載の毒素製剤。 15.5.0と7.3との間のpHを有し、そして賦形剤として安定化蛋白質を含有する 水溶液中の透析し精製された毒素を凍結乾 燥する工程からなる貯蔵−安定化されたボツリヌス毒素医薬製剤の製法。 16.水溶液が燐酸塩緩衝液からなる請求の範囲第15項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90320792A | 1992-06-23 | 1992-06-23 | |
US903,207 | 1992-06-23 | ||
PCT/US1993/005973 WO1994000481A1 (en) | 1992-06-23 | 1993-06-22 | Pharmaceutical composition containing botulinum b complex |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08506083A true JPH08506083A (ja) | 1996-07-02 |
JP3510886B2 JP3510886B2 (ja) | 2004-03-29 |
Family
ID=25417109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50254294A Expired - Fee Related JP3510886B2 (ja) | 1992-06-23 | 1993-06-22 | ボツリヌスb複合体を含有する医薬組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5696077A (ja) |
EP (1) | EP0654040A1 (ja) |
JP (1) | JP3510886B2 (ja) |
AU (2) | AU4646393A (ja) |
CA (1) | CA2138020C (ja) |
WO (1) | WO1994000481A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002524527A (ja) * | 1998-09-11 | 2002-08-06 | エラン ファーマシューティカルズ,インコーポレイテッド | ボツリヌス毒素の安定な液体処方物 |
JP2002531516A (ja) * | 1998-12-10 | 2002-09-24 | ビオテコン ゲゼルシャフト フュア ビオテヒノロギッシェ エントヴィックルング ウント コンズルティンク エムベーハー | いびき音を抑制するための治療剤 |
JP2005533819A (ja) * | 2002-06-26 | 2005-11-10 | アラーガン、インコーポレイテッド | 持続勃起症を処置するためのボツリヌス毒素 |
JP2007262086A (ja) * | 1993-12-28 | 2007-10-11 | Allergan Inc | ジストニーを処置するためのb型ボツリヌス毒素含有医薬組成物 |
JP2012031194A (ja) * | 2000-02-08 | 2012-02-16 | Allergan Inc | ボツリヌス毒素医薬組成物 |
JP2020002136A (ja) * | 2011-01-24 | 2020-01-09 | アンテリオス, インコーポレイテッド | ナノ粒子組成物、その製剤およびその使用 |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
WO1994028923A1 (en) * | 1993-06-10 | 1994-12-22 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
JPH08511536A (ja) * | 1993-06-10 | 1996-12-03 | アラーガン、インコーポレイテッド | 複数の血清型のボツリヌス毒素により、神経筋疾患および症状を処置する方法 |
US20040126396A1 (en) * | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US8557256B2 (en) | 1993-12-28 | 2013-10-15 | Allergan, Inc. | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin |
US8187612B2 (en) | 1993-12-28 | 2012-05-29 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle |
ES2138740T3 (es) * | 1994-05-31 | 2000-01-16 | Allergan Inc | Modificacion de toxinas de clostridium utilizadas como proteinas de transporte. |
WO1996005222A1 (en) * | 1994-08-08 | 1996-02-22 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
ATE239491T1 (de) * | 1995-06-06 | 2003-05-15 | L Bruce Pearce | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen |
WO1996039166A1 (en) * | 1995-06-06 | 1996-12-12 | Wisconsin Alumni Research Foundation | Analogs of botulinum toxin and pharmaceutical compositions of botulinum toxin |
US7537773B1 (en) | 1998-08-25 | 2009-05-26 | Botulinum Toxin Research Associates, Inc. | Chemodenervating pharmaceutical as anti-inflammatory agent |
JP2003512441A (ja) * | 1999-10-22 | 2003-04-02 | アメリカ合衆国 | 極性上皮細胞層を横断するタンパク質の送達 |
US6429189B1 (en) | 1999-12-10 | 2002-08-06 | Botulinum Toxin Research Associates, Inc. | Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US6299893B1 (en) * | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
GB0030008D0 (en) * | 2000-12-08 | 2001-01-24 | Federal Mogul Brake Syst Ltd | Brake limiting |
JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
US6984375B2 (en) * | 2001-08-03 | 2006-01-10 | Allergan, Inc. | Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles |
WO2003073994A2 (en) * | 2002-03-01 | 2003-09-12 | Elan Pharmaceuticals, Inc. | Methods of treating nerve entrapment syndromes |
WO2003082315A1 (fr) * | 2002-03-29 | 2003-10-09 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Remede contre l'hypermyotonie |
US7459164B2 (en) | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
US7238357B2 (en) * | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
WO2004060384A2 (en) * | 2002-12-20 | 2004-07-22 | Botulinum Toxin Research Associates, Inc. | Pharmaceutical botulinum toxin compositions |
ATE538807T1 (de) * | 2003-03-06 | 2012-01-15 | Botulinum Toxin Res Associates Inc | Behandlung von sinusitis-assoziierten beschwerden mit botulinum toxin |
US6974579B2 (en) * | 2004-01-08 | 2005-12-13 | Allergan, Inc. | Methods for treating vascular disorders |
US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
AU2005296064A1 (en) * | 2004-10-04 | 2006-04-27 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of macromolecules |
US8192979B2 (en) * | 2005-01-03 | 2012-06-05 | Botulinum Toxin Research Associates, Inc. | Compositions, methods and devices for preparing less painful Botulinum toxin formulations |
US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US7744904B1 (en) * | 2005-09-26 | 2010-06-29 | B.B. Scientific L.L.C. | Stabilization of Clostridium botulinum neurotoxin complex |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
US20070148131A1 (en) * | 2005-12-05 | 2007-06-28 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of binding partners |
CA2631952A1 (en) * | 2005-12-05 | 2007-06-14 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of antibodies |
US20090305978A1 (en) * | 2006-03-16 | 2009-12-10 | Trinity Biosystems, Inc. | Methods for increasing the size of animals using needleless delivery constructs |
US20090092660A1 (en) * | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
CN100577149C (zh) * | 2006-12-21 | 2010-01-06 | 北京民海生物科技有限公司 | 一种治疗用a型肉毒毒素冻干粉针剂新型冻干保护剂配方 |
CA2699435A1 (en) | 2007-09-14 | 2009-03-19 | Sanofi Pasteur Biologics Co. | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
EP3556770A1 (en) | 2008-03-14 | 2019-10-23 | Allergan, Inc. | Immuno-based botulinum toxin serotype a activity assays |
US20100124559A1 (en) * | 2008-11-20 | 2010-05-20 | Allergan, Inc. | Early Treatment and Prevention of Increased Muscle Tonicity |
US9066851B2 (en) | 2008-12-04 | 2015-06-30 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
JP5792718B2 (ja) | 2009-06-24 | 2015-10-14 | ソパーカー、チャールズ エヌ.エス.SOPARKAR,Charles N.S. | 処置前治療用メタロプロテアーゼ準備パック |
US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
EP2305290A1 (en) * | 2009-10-05 | 2011-04-06 | Merz Pharma GmbH & Co. KGaA | Salt-free composition comprising an intact Botulinum toxin complex |
WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
US20140120077A1 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and Methods for Safe Treatment of Rhinitis |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
RU2019110875A (ru) | 2016-09-13 | 2020-10-15 | Аллерган, Инк. | Небелковые композиции клостридиального токсина |
KR102463881B1 (ko) | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
MX2019005833A (es) * | 2016-11-21 | 2019-10-30 | Eirion Therapeutics Inc | Administracion transdermica de agentes grandes. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2059970B (en) * | 1979-09-11 | 1983-06-02 | Novo Industri As | Spasmolytic polypeptide |
JPS5668607A (en) * | 1979-11-07 | 1981-06-09 | Teikoku Hormone Mfg Co Ltd | Medical preparation with storage stability |
US4932936A (en) * | 1988-01-29 | 1990-06-12 | Regents Of The University Of Minnesota | Method and device for pharmacological control of spasticity |
US5053005A (en) * | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
WO1994028923A1 (en) * | 1993-06-10 | 1994-12-22 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
JPH08511536A (ja) * | 1993-06-10 | 1996-12-03 | アラーガン、インコーポレイテッド | 複数の血清型のボツリヌス毒素により、神経筋疾患および症状を処置する方法 |
-
1993
- 1993-06-22 AU AU46463/93A patent/AU4646393A/en not_active Abandoned
- 1993-06-22 WO PCT/US1993/005973 patent/WO1994000481A1/en not_active Application Discontinuation
- 1993-06-22 EP EP93916689A patent/EP0654040A1/en not_active Ceased
- 1993-06-22 CA CA002138020A patent/CA2138020C/en not_active Expired - Lifetime
- 1993-06-22 JP JP50254294A patent/JP3510886B2/ja not_active Expired - Fee Related
-
1994
- 1994-10-03 US US08/316,820 patent/US5696077A/en not_active Expired - Lifetime
-
1997
- 1997-03-14 AU AU16292/97A patent/AU1629297A/en not_active Abandoned
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007262086A (ja) * | 1993-12-28 | 2007-10-11 | Allergan Inc | ジストニーを処置するためのb型ボツリヌス毒素含有医薬組成物 |
JP2012197287A (ja) * | 1993-12-28 | 2012-10-18 | Allergan Inc | ジストニーを処置するためのb型ボツリヌス毒素含有医薬組成物 |
JP2002524527A (ja) * | 1998-09-11 | 2002-08-06 | エラン ファーマシューティカルズ,インコーポレイテッド | ボツリヌス毒素の安定な液体処方物 |
JP2010138186A (ja) * | 1998-09-11 | 2010-06-24 | Solstice Neurosciences Inc | ボツリヌス毒素の安定な液体処方物 |
JP2002531516A (ja) * | 1998-12-10 | 2002-09-24 | ビオテコン ゲゼルシャフト フュア ビオテヒノロギッシェ エントヴィックルング ウント コンズルティンク エムベーハー | いびき音を抑制するための治療剤 |
JP4700811B2 (ja) * | 1998-12-10 | 2011-06-15 | メルツ・ファルマ・ゲゼルシヤフト・ミット・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンディトゲゼルシヤフト・アウフ・アクティーン | いびき音を抑制するための治療剤 |
JP2012031194A (ja) * | 2000-02-08 | 2012-02-16 | Allergan Inc | ボツリヌス毒素医薬組成物 |
JP2005533819A (ja) * | 2002-06-26 | 2005-11-10 | アラーガン、インコーポレイテッド | 持続勃起症を処置するためのボツリヌス毒素 |
JP2010222367A (ja) * | 2002-06-26 | 2010-10-07 | Allergan Inc | 持続勃起症を処置するためのボツリヌス毒素 |
JP2013166792A (ja) * | 2002-06-26 | 2013-08-29 | Allergan Inc | 持続勃起症を処置するためのボツリヌス毒素 |
JP2020002136A (ja) * | 2011-01-24 | 2020-01-09 | アンテリオス, インコーポレイテッド | ナノ粒子組成物、その製剤およびその使用 |
Also Published As
Publication number | Publication date |
---|---|
CA2138020A1 (en) | 1994-01-06 |
US5696077A (en) | 1997-12-09 |
WO1994000481A1 (en) | 1994-01-06 |
JP3510886B2 (ja) | 2004-03-29 |
CA2138020C (en) | 1999-02-16 |
EP0654040A1 (en) | 1995-05-24 |
AU4646393A (en) | 1994-01-24 |
AU1629297A (en) | 1997-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3510886B2 (ja) | ボツリヌスb複合体を含有する医薬組成物 | |
US6635247B2 (en) | Hypoparathyroid therapy | |
US5846929A (en) | Purification of type G botulinum neurotoxin and pharmaceutical compositions thereof | |
Schantz et al. | Botulinum toxin: the story of its development for the treatment of human disease | |
EP0889730B1 (en) | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation | |
US6087327A (en) | Compositions and methods for chemodenervation using neurotoxins | |
CN100389820C (zh) | 含肉毒神经毒素的治疗剂 | |
DE69434511T2 (de) | Botulinumtoxin zur Behandlung von Dystonie | |
ES2287117T3 (es) | Uso de una toxina botulinica pra la fabricacion de un medicamento de administracion periferica para tratar dolor no asociado al espasmo muscular ni al dolor de cabeza. | |
US20170224786A1 (en) | Botulinum toxin compositions | |
DE60110372T2 (de) | Pharmazeutische zusammensetzungen mit botulinumtoxin | |
DE69731357T2 (de) | Funktionelles antigenfragment von tetanustoxin und tetanusvakzine | |
US5817617A (en) | Selectin and pertussis toxin derived peptides and uses thereof | |
KR20100020972A (ko) | 보툴리늄 톡신의 신경독 성분에 기초한 온도-안정한 근육 이완제를 제공하는 방법 | |
WO2021195968A1 (zh) | A型肉毒杆菌毒素复合物、其配制剂和使用方法 | |
Borodic et al. | Botulinum B toxin as an alternative to botulinum A toxin: a histologic study | |
CN100577149C (zh) | 一种治疗用a型肉毒毒素冻干粉针剂新型冻干保护剂配方 | |
TWI739368B (zh) | A型肉毒桿菌毒素複合物、其配製劑和使用方法 | |
Daugharty | Study of antibodies in human sera against staphylococcal poly-saccharide and type-specific antigens | |
DE20023785U1 (de) | Therapeutikum mit einem Botulinum-Neurotoxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040105 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090109 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100109 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110109 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110109 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120109 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130109 Year of fee payment: 9 |
|
LAPS | Cancellation because of no payment of annual fees |